Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Cellectis S.A. Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis…
PTC Therapeutics, Inc. Common Stock Offering
Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of …
Davis Polk Advises iKang Healthcare on Its Acquisition by Yunfeng Capital and Alibaba
Davis Polk is advising iKang Healthcare Group, Inc. in connection with its acquisition for $41.20 per common share or $20.60…
Accelerate Diagnostics, Inc. $150 Million Convertible Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Accelerate…
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $1.5 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction…
Xencor, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of…
Corvus Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by…
Davis Polk Advises Agilent Technologies on Its Acquisition of Advanced Analytical Technologies
Davis Polk is advising Agilent Technologies, Inc. on its acquisition of privately held Advanced Analytical Technologies, Inc…
Atara Biotherapeutics, Inc. Follow-On Offerings
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two…